New regimens as first‐line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial

Abstract

AbstractBackgroundHelicobacter pylori eradication in penicillin‐allergic patients is challenging. The effective regimen is lacking in areas with high antibiotic resistance and tetracycline unavailable. Minocycline, cefuroxime, and full‐dose metronidazole are promising drugs.AimsTo compare the eradication rate, safety, and compliance among three new bismuth quadruple therapies for first‐line H. pylori eradication in penicillin‐allergic patients.MethodsThis randomized trial was conducted on 450 naive patients with H. pylori infection and penicillin allergy. The 14‐day minocycline‐metronidazole‐containing (minocycline 100 mg twice daily and metronidazole 400 mg four times/day), minocycline‐cefuroxime‐containing (minocycline 100 mg twice daily and cefuroxime 500 mg twice daily), and cefuroxime‐metronidazole‐containing (cefuroxime 500 mg twice daily and metronidazole 400 mg four times/day) bismuth quadruple therapies were randomly assigned to the participants. Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed 4–8 weeks after eradication to evaluate outcome.ResultsThe differences of eradication rates in either intention‐to‐treat (84.0%, 82.7%, and 23 82.0%, p = .896) or per‐protocol (91.7%, 90.9%, and 88.2%, p = .599) analysis among minocycline‐metronidazole, minocycline‐cefuroxime, and cefuroxime‐metronidazole‐containing bismuth quadruple therapies were statistically insignificant. The incidence of adverse events (35.1%, 22.6%, and 28.9%) and compliance (90.5%, 91.8%, and 91.9%) were similar. Taste distortion, nausea, and anorexia were more common in metronidazole‐containing regimens, and dizziness was more common in minocycline‐containing regimens. The allergy was rare (~3%).ConclusionsThe efficacies of three bismuth quadruple therapies containing minocycline, cefuroxime, and full‐dose metronidazole (pairwise) for first‐line H. pylori eradication in penicillin‐allergic patients were similarly satisfactory with relatively good safety and compliance. The study was registered in the Chinese Clinical Trials Registration (ChiCTR1900023702).